NKTR

Nektar Therapeutics Press Releases

$15.225
*  
0.205
1.36%
Get NKTR Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading NKTR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
12/11/2014 6:00:00 PM - PR Newswire
▼-2.40 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting
12/9/2014 8:00:00 AM - PR Newswire


Hudson City Bancorp, Inc. And M&T Bank Corporation Announce Further Extension Of Time To Complete Proposed Merger To April 30, 2015
12/9/2014 8:00:00 AM - PR Newswire


Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
12/1/2014 9:18:00 AM - PR Newswire
▼-8.67 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A
12/1/2014 9:00:00 AM - Business Wire


FDA Grants QIDP Designation to Bayer''s Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation
11/24/2014 10:12:00 AM - PR Newswire


Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model
11/20/2014 9:00:00 AM - PR Newswire


Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014
11/6/2014 4:10:00 PM - PR Newswire
▲12.28 % Price Change since this news event. The Volume Ratio is 2.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets
10/30/2014 8:30:00 AM - PR Newswire
▲9.69 % Price Change since this news event. The Volume Ratio is 1.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day